Evidence map›Paper›PMID 42189900›Full record

ArticlePLoS computational biology2026

MIAAIM: Multi-omics image integration with dimensional reduction for tissue state mapping.

Joshua M Hess, Richard K Dzeng, Iulian Ilieş, Denis Schapiro, John J Iskra, Divya Mirgh, John Nam, Erin H Seeley, David E Verrill, Walid M Abdelmoula and 9 more

Abstract read
In one paragraph

Article in PLoS computational biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Joshua M HessVaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0000-0003-3776-1092
Richard K DzengVaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0000-0002-3664-8883
Iulian IlieşHealthcare Systems Engineering Institute, Northeastern University, Boston, Massachusetts, United States of America.
Denis SchapiroLaboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0000-0002-9391-5722
John J IskraVaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Divya MirghVaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0009-0001-1507-1616
John NamVaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0000-0002-9604-0159
Erin H SeeleyDepartment of Chemistry, University of Texas, Austin, Texas, United States of America.ORCID https://orcid.org/0000-0002-8000-5754
David E VerrillChemistry and Chemical Biology, Barnett Institute for Chemical & Biological Analysis, Northeastern University, Boston, Massachusetts, United States of America.
Walid M AbdelmoulaDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Michael S ReganDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Georgios TheocharidisThe Rongxiang Xu Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America.
Chin Lee WuDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Aristidis VevesThe Rongxiang Xu Center for Regenerative Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America.
Nathalie Y R AgarDepartment of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Ann E SluderVaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Mark C PoznanskyVaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.
Ruxandra F SîrbulescuVaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0000-0001-7905-1713
Patrick M ReevesVaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0000-0001-8202-0723

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-parameter tissue imaging enables detailed molecular analysis of single cells within their spatial environment. A current challenge to more complete tissue and single-cell spatial profiling is in situ data alignment across imaging platforms that quantify multiple types of biomolecules at differing resolutions. Here, we describe MIAAIM (Multi-omics Image Alignment and Analysis by Information Manifolds), a modular framework to align and process data from separate imaging technologies with distinct imaging resolutions and data complexity. MIAAIM is designed to be applied to align and analyze images of clinical biopsies from histological staining, imaging mass cytometry, and mass spectrometry imaging. A key advantage of the MIAAIM approach is its capacity to identify unbiased molecular phenotypes that correlate with cell identities and states determined using high-resolution targeted immunodetection. In a large diabetic foot ulcer (DFU) biopsy, this strategy allowed the identification of unique molecular characteristics of infiltrating immune cells as a function of local tissue health. In multi-core tissue microarrays (TMAs) of prostate cancer, MIAAIM allowed the classification of adjacent tumor grades with high accuracy, with over 90% of classification signal sourced from spatial features, generated from segmented cells across multiple imaging modalities while revealing novel cell/ immune signatures of the disease state. MIAAIM provides a disease and cell type agnostic general framework to construct multimodal tissue imaging datasets, yielding novel insights into the association of molecular analytes with cell subsets and their activation states for the analysis of complex tissue states.

Indexed as

Image Processing, Computer-AssistedComputational BiologyDiabetic FootHumansMaleMass SpectrometryMultiomicsProstatic NeoplasmsTissue Array Analysis

Identifiers

PMID42189900
PMCPMC13225665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.